Cabaletta Bio, Inc.

CABA

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001759138

None

No letter

6 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $165.1M
Warnings	dilution, thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	6 of 13
Graded from	filings received through Mar 23, 2026 240 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$1.01 2026-11-17; market equity $219.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA®, or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 19.6						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(21.0%)	(6.7%)	19.6	756	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 71.4						
Altman Z double-prime	(11.48)	0.31	65.8	705	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	(85.95x)	(3.61x)	89.0	74	2025-12-31	
Current ratio	2.77x	2.68x	59.4	781	2025-12-31	
Growth and financing, sleeve percentile 56.7						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
one or more required annual facts are missing						
Asset growth, three years	12.2%	3.2%	28.7	663	2025-12-31	
Net share issuance, one year	119.4%	1.6%	84.8	625	2026-03-19	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 119.4%
Thin data	6 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(46.8%)	(1.7%)	17
Distance from 52-week high	(75.4%)	(30.5%)	11
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(60.1%)	0.5%	12
Book value to price	1.29	0.28	90
Sales to price	not computable	0.36	
Composite equity issuance, five years	219.3%	13.5%	92
Relative strength against the sector, log excess return	(0.80)	(0.19)	17
Twelve-month failure probability, CHS model	0.21%	0.06%	75

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$299.4M
Operating cash flow, four quarters	-$162.2M
Months of runway	22.2
Days since last periodic filing	13 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$10.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$167.9M	2025-12-31	2026-03-23	10-K	26-000011
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$131.1M	2025-12-31	2026-03-23	10-K	26-000011
3	assets	us-gaap:Assets	$165.1M	2025-12-31	2026-03-23	10-K	26-000011
4	assets	us-gaap:Assets	$185.0M	2024-12-31	2026-03-23	10-K	26-000011
5	current assets	us-gaap:AssetsCurrent	$138.9M	2025-12-31	2026-03-23	10-K	26-000011
6	current liabilities	us-gaap:LiabilitiesCurrent	$50.2M	2025-12-31	2026-03-23	10-K	26-000011
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$517.0M	2025-12-31	2026-03-23	10-K	26-000011
8	operating income	us-gaap:OperatingIncomeLoss	-$172.2M	2025-12-31	2026-03-23	10-K	26-000011
9	book equity	us-gaap:StockholdersEquity	$112.1M	2025-12-31	2026-03-23	10-K	26-000011
10	liabilities	us-gaap:Liabilities	$53.0M	2025-12-31	2026-03-23	10-K	26-000011
11	interest expense	us-gaap:InterestExpense	$2.0M	2025-12-31	2026-03-23	10-K	26-000011
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2M	2025-12-31	2026-03-23	10-K	26-000011
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$88.2M	2024-12-31	2026-03-23	10-K	26-000011
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2M	2024-12-31	2026-03-23	10-K	26-000011
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$53.5M	2023-12-31	2025-03-31	10-K	25-047201
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$687,000	2023-12-31	2025-03-31	10-K	25-047201
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$46.4M	2022-12-31	2024-03-21	10-K	24-034422
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2022-12-31	2024-03-21	10-K	24-034422
19	assets	us-gaap:Assets	$253.7M	2023-12-31	2025-03-31	10-K	25-047201
20	assets	us-gaap:Assets	$117.0M	2022-12-31	2024-03-21	10-K	24-034422
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	111,322,671	2026-03-19	2026-03-23	10-K	26-000011
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	50,743,101	2025-03-27	2025-03-31	10-K	25-047201

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.